These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Combined nicotinic and muscarinic blockade in elderly normal volunteers: cognitive, behavioral, and physiologic responses. Little JT; Johnson DN; Minichiello M; Weingartner H; Sunderland T Neuropsychopharmacology; 1998 Jul; 19(1):60-9. PubMed ID: 9608577 [TBL] [Abstract][Full Text] [Related]
7. Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans. Martinez R; Molchan SE; Lawlor BA; Thompson K; Martinson H; Latham G; Weingartner H; Sunderland T Biol Psychiatry; 1997 Jan; 41(1):50-7. PubMed ID: 8988795 [TBL] [Abstract][Full Text] [Related]
8. The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls. Broocks A; Little JT; Martin A; Minichiello MD; Dubbert B; Mack C; Tune L; Murphy DL; Sunderland T Biol Psychiatry; 1998 Mar; 43(6):408-16. PubMed ID: 9532345 [TBL] [Abstract][Full Text] [Related]
9. Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia. Wesnes K; Anand R; Lorscheid T Acta Psychiatr Scand Suppl; 1990; 360():71-2. PubMed ID: 2248080 [TBL] [Abstract][Full Text] [Related]
10. Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. Flicker C; Serby M; Ferris SH Psychopharmacology (Berl); 1990; 100(2):243-50. PubMed ID: 2305013 [TBL] [Abstract][Full Text] [Related]
11. Effects of scopolamine on matching to sample paradigm and related tests in human subjects. Koller G; Satzger W; Adam M; Wagner M; Kathmann N; Soyka M; Engel R Neuropsychobiology; 2003; 48(2):87-94. PubMed ID: 14504417 [TBL] [Abstract][Full Text] [Related]
12. Continuous ICV infusion of scopolamine impairs sustained attention of rhesus monkeys. Callahan MJ; Kinsora JJ; Harbaugh RE; Reeder TM; Davis RE Neurobiol Aging; 1993; 14(2):147-51. PubMed ID: 8487917 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Litvan I; Blesa R; Clark K; Nichelli P; Atack JR; Mouradian MM; Grafman J; Chase TN Ann Neurol; 1994 Jul; 36(1):55-61. PubMed ID: 8024262 [TBL] [Abstract][Full Text] [Related]
15. Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Vitiello B; Martin A; Hill J; Mack C; Molchan S; Martinez R; Murphy DL; Sunderland T Neuropsychopharmacology; 1997 Jan; 16(1):15-24. PubMed ID: 8981385 [TBL] [Abstract][Full Text] [Related]
16. Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer's dementia: a neuropsychological and computerized electroencephalographic study. Agnoli A; Martucci N; Manna V; Conti L; Fioravanti M Clin Neuropharmacol; 1983; 6(4):311-23. PubMed ID: 6661730 [TBL] [Abstract][Full Text] [Related]
17. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Kennedy DO; Wake G; Savelev S; Tildesley NT; Perry EK; Wesnes KA; Scholey AB Neuropsychopharmacology; 2003 Oct; 28(10):1871-81. PubMed ID: 12888775 [TBL] [Abstract][Full Text] [Related]
18. Central cholinergic pathway involvement in the regulation of pupil diameter, blink rate and cognitive function. Naicker P; Anoopkumar-Dukie S; Grant GD; Neumann DL; Kavanagh JJ Neuroscience; 2016 Oct; 334():180-190. PubMed ID: 27531858 [TBL] [Abstract][Full Text] [Related]
19. The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine. Fredrickson A; Snyder PJ; Cromer J; Thomas E; Lewis M; Maruff P Hum Psychopharmacol; 2008 Jul; 23(5):425-36. PubMed ID: 18421801 [TBL] [Abstract][Full Text] [Related]